Publications by authors named "Vladimer Kuchava"
Article Synopsis
- A study showed that combining the immunotherapy drug serplulimab with chemotherapy improves survival for advanced squamous non-small-cell lung cancer patients who don't have specific targetable gene alterations.
- Researchers enrolled 537 previously untreated patients, and results indicated that the serplulimab group had significantly better progression-free survival (PFS) and overall survival (OS) compared to those receiving only chemotherapy.
- While both treatments had side effects, the adverse events were considered manageable, highlighting the potential of this combination approach in treating advanced NSCLC.
Background: Bevacizumab is an antiangiogenic recombinant humanized monoclonal antibody that inhibits tumor growth. FKB238, a bevacizumab biosimilar, has analytical pharmacokinetic and safety profiles similar to those of bevacizumab.
Objective: This phase III trial (NCT02810457) compared the efficacy and safety of FKB238 with that of bevacizumab in patients with advanced/recurrent non-squamous non-small-cell lung cancer (non-sq-NSCLC).
Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy-induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezolizumab (E/P/A) were evaluated in a randomised, double-blind, placebo-controlled Phase II study in patients with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC) (NCT03041311). The primary endpoints were duration of severe neutropenia (SN; defined as absolute neutrophil count <0.
View Article and Find Full Text PDF